Submissions that are incomplete or received after the deadline will not be considered. All ESA Annual Meeting proposal and abstract deadlines are 5:00 PM Eastern so that technical support and ESA ...
PHILADELPHIA and VANCOUVER, British Columbia, May 23, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ), (TSX: BCT) (“BriaCell” or ...
Final randomized Phase 2 Bria-IMT™ survival and quality of life data to be presented Biomarker analyses from the ongoing Phase 3 study evaluating predictors of response Date and Time: June 1, 2026, ...
Did you know the ESA annual meeting receives twice as many contributed abstracts for talks compared to posters? Over the past decade, only 1 out of every 3 contributed abstracts has been submitted for ...
Publication-Only Abstract Title: Cell-based second-generation immunotherapy BC1 in metastatic breast cancer. Publication-Only Abstract Title: Liquid biopsy to stratify metastatic breast cancer ...
Final randomized Phase 2 Bria-IMT™ survival and quality of life data to be presented Biomarker analyses from the ongoing Phase 3 study evaluating predictors of response PHILADELPHIA and VANCOUVER, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results